Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
Public ClinicalTrials.gov record NCT00638898. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pilot Study of High-Dose Chemotherapy With Busulfan, Melphalan, and Topotecan Followed by Autologous Hematopoietic Stem Cell Transplant in Advanced Stage and Recurrent Tumors
Study identification
- NCT ID
- NCT00638898
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- City of Hope Medical Center
- Other
- Enrollment
- 25 participants
Conditions and interventions
Conditions
- Adult Central Nervous System Germ Cell Tumor
- Adult Rhabdomyosarcoma
- Childhood Central Nervous System Germ Cell Tumor
- Childhood Soft Tissue Sarcoma
- Ewing Sarcoma
- Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Ovarian Mixed Germ Cell Tumor
- Previously Untreated Childhood Rhabdomyosarcoma
- Recurrent Adult Brain Tumor
- Recurrent Adult Soft Tissue Sarcoma
- Recurrent Childhood Brain Stem Glioma
- Recurrent Childhood Cerebellar Astrocytoma
- Recurrent Childhood Cerebral Astrocytoma
- Recurrent Childhood Ependymoma
- Recurrent Childhood Malignant Germ Cell Tumor
- Recurrent Childhood Medulloblastoma
- Recurrent Childhood Pineoblastoma
- Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
- Recurrent Childhood Visual Pathway Glioma
- Recurrent Childhood Visual Pathway and Hypothalamic Glioma
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Recurrent Extragonadal Germ Cell Tumor
- Recurrent Extragonadal Non-seminomatous Germ Cell Tumor
- Recurrent Malignant Testicular Germ Cell Tumor
- Recurrent Neuroblastoma
- Recurrent Ovarian Germ Cell Tumor
- Recurrent Wilms Tumor and Other Childhood Kidney Tumors
- Solid Tumor
- Unspecified Adult Solid Tumor, Protocol Specific
- Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
- autologous bone marrow transplantation Procedure
- autologous hematopoietic stem cell transplantation Procedure
- busulfan Drug
- filgrastim Biological
- laboratory biomarker analysis Other
- melphalan Drug
- pharmacological study Other
- topotecan hydrochloride Drug
Procedure · Drug · Biological + 1 more
Eligibility (public fields only)
- Age range
- 6 Months to 40 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 25, 2007
- Primary completion
- Jan 18, 2013
- Completion
- Dec 9, 2024
- Last update posted
- Mar 19, 2025
2007 – 2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00638898, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 19, 2025 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00638898 live on ClinicalTrials.gov.